Abstract
Background. It is well known that renal cell carcinoma (RCC) is one of the most important complications in haemodialysis (HD) patients. However, the influence of HD duration on the development of RCCs has not yet been described. This study sought to determine whether HD duration is related to pathological RCC types and to prognosis. Methods. We examined 69 patients having HD (73 kidneys) who underwent radical nephrectomy for renal tumours between 1991 and 2008. We divided the patients into three groups according to the duration of HD (<10 years, between 10 and 20 years, and >20 years). All histological examinations were performed without knowledge of clinical outcomes. In each case, pathological cell types and clinical parameters were recorded. Results. The patients with HD duration of > 10 years showed distinct pathological characteristics, including acquired cystic disease of kidney-associated RCCs. The disease-free survival (DFS) rates of these groups were statistically different from one another (P < 0.05). RCC with a sarcomatoid component was found in cases having HD durations of >10 years. The DFS rate of the patients with a sarcomatoid component was 55.9% at 5 years and 37.3% at 10 years. Conclusions. HD duration influenced pathological cell types and tumour stages of RCCs in HD patients. Patients receiving >10 years of HD experienced RCCs with a sar-
Introduction
It is well known that renal cell carcinomas (RCCs) are one of the major complications in haemodialysis (HD) patients [1] [2] [3] . Maisonneuve et al. [4] reported that~3% of HD patients had RCCs and that the standard incidence ratio was 3.6 times higher than in HD patients with normal renal function. The histopathological characteristics of RCCs in HD patients are unique and different from those of ordinary RCCs [5] . For example, acquired cystic disease of kidney (ACDK)-associated carcinoma is a unique subtype of RCC that is observed only in ACDK patients, most of whom are end-stage renal disease (ESRD) or HD patients. Although some studies revealed that RCCs occur in ACDK patients, including HD patients assessed using a pathological spectrum based on duration of HD, the cell types and the prognosis of RCC associated with ESRD or HD are not well described. Setoguchi et al. [6] reported that prognosis of patients with RCC who received HD for >20 years was worse than those who received HD for <20 years. However, little is known about the relation between RCC and long-term HD.
In the present study, we evaluated histopathologic characteristics and prognostic factors of RCCs in HD patients according to duration of HD.
Materials and methods

Patients
Seventy-five cases of RCC in HD patients who underwent radical nephrectomy for renal tumours between January 1991 and December 2008 were retrieved from the files of the authors and from affiliated institutions. Of these cases, two were excluded because of benign tumours. Of the remaining 73 RCC cases, 69 were included in this study. This study received the approval of the institutional review board, and all participating sites provided the necessary institutional data sharing agreements before initiation.
The HD patients were given periodic medical examinations each year during the study. Screening examinations for kidney tumours were diagnosed using ultrasound. Patients with suspected RCC were given additional examinations (enhanced computer tomography and/or magnetic response imaging). Postoperative follow-up was established according to protocols at each institution.
RCC patients received long term HD. We divided the RCC patients receiving HD into three groups: <10 years, between 10 and 20 years, and >20 years. Ishikawa [7] reported that patients who received HD for >10 years had a higher RCC occurrence rate than those with <10 years. Setoguchi et al. reported [6] that RCC patients who received >20 years of HD died from RCC.
Pathological evaluation
Haematoxylin-eosin-stained slides from all the cases were available for review. All the slides were reviewed by a genitourinary pathologist (T.T.) who was blinded to the clinical outcome. Pathological tumour stage and nuclear grade were determined according to the 2002 American Joint Committee on Cancer/International Union against Cancer TNM classification and Fuhrman grading. In each case, the following pathological parameters were evaluated: age, sex, duration of dialysis, laterality, pathological T stage, ACDK, surgical technique, histological type (according to the World Health Organization classification [8, 9] ), Fuhrman grade, lympho-vascular invasion and necrosis.
Statistical analysis
Disease-free survival (DFS) and cancer-specific survival (CSS) were analysed with the log-rank test using the statistical package for social sciences (SPSS) software (version 15.0; Chicago, USA). We analysed the factors affecting prognosis in HD patients using multivariate analysis and analysed histopathological parameters using the log-rank, Cox hazard and Kruskal-Wallis tests. P-values of <0.05 were considered significant.
Results
Patient characteristics
Patient characteristics are listed in Table 1 . In this study, 69 patients were divided into three groups according to HD duration. Group 1 consisted of 24 patients who received HD for <10 years (32.9%), Group 2 consisted of 26 patients who received HD between 10 and 20 years (35.6%) and Group 3 consisted of 23 patients who received HD for >20 years (31.5%). In these patients, the original disease causing chronic renal failure did not include a history of malignant tumour of the kidney. Most of the patients had no symptoms, and most of the tumours were detected with magnetic response imaging, computer tomography and ultrasonography. In addition, 56 cases (81.2%) had ACDK at the time of surgery.
Three of the four patients with bilateral RCC underwent bilateral nephrectomy at the same time. The fourth case underwent bilateral nephrectomy at asynchronous times. Lymph node dissections were not routinely performed in most of the cases. All the tumours were completely resected.
Clinical results
In total, 69 cases were observed for a mean of 3.23 observation years, and patient characteristics are shown in Table 1 . Of the 69 cases, 5 (6.4%) died of recurrent disease and 4 (5.1%) showed recurrences at the following sites: lung, bone and local. In addition, seven patients (9.0%) died from unrelated causes without recurrence and metastasis.
We investigated DFS on the basis of HD duration and compared DFS in a subset of patients who were classified according to the duration of HD. In Group 1 patients, DFS was 100% at 10 years, in Group 2 it was 84.2% at 10 years and in Group 3 it was 55.9% at 5 years and 37.3% at 10 years (P < 0.05) ( Figure 1A ).
RCC patients who received HD for <10 years did not show any recurrence. Recurrence of RCC was observed in patients having >10 years of HD and the rate increased with increasing duration.
Pathological results
Specimens from 73 malignant tumours were histopathologically analysed, and results are listed in Table 2 . Patho-logical T stage, Fuhrman grade and presence of ACDK were significantly different between the three groups.
Most of the patients who received HD for <10 years were pT1. As the HD duration increased, the cancer stage of the patients also increased (P = 0.003).
Across all cases, the most common histological type was clear cell carcinoma (32 cases; 43.8%), and the second most common was ACDK-associated carcinoma (17 cases; 23.3%). Clear papillary cell carcinoma was not distinguished. The histological types found in RCC patients who received HD for <10 years were similar to those in sporadic RCC patients with normal kidney function. In patients with HD duration of >10 years, ACDK-associated carcinomas were observed more frequently. Interestingly, all of the ACDK-associated carcinomas were of low pathological stage. In patients with HD duration of >10 years, the incidence of RCC with a sarcomatoid component increased. There were two RCC patients with HD duration between 10 and 20 years and six cases with HD duration of > 20 years. Nine of the eight Fuhrman grade 4 cases included a sarcomatoid component. The incidence of RCC with a sarcomatoid component increased in patients having >20 years HD (P = 0.01).
The distribution of pathological types was significantly different between the three groups (P < 0.01). In addition, DFS rates between each histological type were also significantly different (P < 0.001) ( Figure 1B ). In total, five cases had recurrent carcinoma and two died from RCC. Prognosis of RCC with a sarcomatoid component was poorer than with other histological types.
Prognostic factors
We compared histopathological prognostic factors in a subset of patients who showed the presence of each factor using the Cox regression test (Table 3 ). In univariate analysis, the presence of necrosis, lympho-vascular invasion, sarcomatoid component and pathological T stage were statistically significant as prognostic factors (P < 0.001). In multivariate analysis, the presence of lympho-vascular invasion, sarcomatoid component and pathological T stage were significant prognostic factors for DFS.
Discussion
It is well known that RCC is one of the major complications in HD patients [1] [2] [3] . Ishikawa et al. [1] reported that the onset of RCC in HD patients per year was 1910/million patients. They also showed that the RCC incidence rate depended on HD duration: for patients with normal kidney function, the incidence was 700/million; for patients receiving HD for <10 years, it was 1120/million (1.6 times the normal kidney function); for patients receiving HD for 10 to 20 years, it was 4380/million (6.3 times the normal kidney function); and for patients receiving HD for >20 years, the incidence was 5560/million (7.9 times the normal kidney function). In patients with a HD duration of >10 years, RCCs were seen to increase rapidly [1, 7] . In Japan, the overall survival rate of patients on HD is 59.9% at 5 years, 37.1% at 10 years, 23.6% at 15 years, 17.4% at 20 years and 16.7% at 25 years. P-values < 0.05 considered significant; n.s., non-significant.
The characteristics for RCC in HD patients
However, there is little information on the influence of HD duration on pathological cell types and diagnosis of RCC, especially in HD cases lasting >10 years. In our study, the median HD duration was 12.1 years (0.6-36 years), and the median follow-up period was 3.23 years.
Some investigators have reported a good prognosis in RCC patients having <10 years of HD [1, 6, 7] . In these studies, the 5-year CSS rate ranged from 91.7 to 93.4%. In the current study, RCC patients having <10 years of HD had a similar prognosis as sporadic RCC patients in the general population; most of the RCC cases were clear cell carcinomas. Interestingly, the nuclear grades of all these patients were low, which indicated that these cases were clinically indolent. However, the reasons for this finding are still unclear.
There are only a few reports of RCC patients who received HD for >10 years. The occurrence rate of ACDK was >90% in patients with a HD duration of >10 years [1] . In our study, all of the RCC patients with HD duration of >10 years had ACDK. Recently, Tickoo et al. [9] proposed a unique histopathologic entity of ACDK-associated RCC, which had already been recognized in Japan [10] . The clinical behaviour of ACDK-associated RCCs, especially those that develop in the context of ACDK, has been well described. In our study, the incidence of ACDK-associated carcinoma increased with the duration of HD (>10 years). In addition, these patients had no recurrence and showed a good prognosis; these results are similar to those of Tickoo et al. [9] . Compared with sporadic RCCs, ACDK-associated RCCs are usually seen in earlier stages, with a lower metastatic rate and better prognosis [11] . These data are consistent with reports showing that ACDK-associated RCCs have a low-grade malignancy. Recently, we experienced a case of ACDK-associated RCC with a sarcomatoid component (unpublished data). Because of the short follow-up, the prognosis of this case remained unknown. However, it is important to note that ACDK-associated RCCs can transform to RCCs with a sarcomatoid component.
Our study revealed that RCC with a sarcomatoid component appeared after 10 years of HD and that the incidence of RCCs with a sarcomatoid component increased (26.1%) with an increasing duration of HD. A sarcomatoid component is known to occur in various RCC cases. The presence of a sarcomatoid component is thought to represent the transformation of ordinary RCCs to a highly malignant and aggressive form. A higher proportion of transformation to a sarcomatoid component has been associated with poorer survival in previous studies. Tickoo et al. [9] reported two cases of sarcomatoid carcinoma in patients having 14 and 15 years of HD. The latter patient died of the disease. Their report did not include cases receiving >20 years of HD. Our study included 23 cases having >20 years of HD, of whom 6 had a sarcomatoid component. We report for the first time that patients who receive long term HD, especially for > 20 years, have a higher risk for developing RCC with a sarcomatoid component. While comparing DFS rates, we found a significant difference between RCC patients having a sarcomatoid component and those without (P < 0.001) ( Figure 1B) . Our study revealed that as the duration of HD increased, the pathological stage increased significantly (P = 0.003). RCC patients having >20 years of HD tended to suffer from rapid-growing carcinomas such as a sarcomatoid component, which were high grade and seen to be at an advanced stage. We speculate that this high-grade component is responsible for their high recurrence rate and poorer prognosis.
Setoguchi et al. [6] reported that RCC patients having >20 years of HD had a poor prognosis (DFS rate was 68.2% at 5 years). Our study also showed that RCC patients having HD for > 20 years had a poor prognosis (DFS rate was 81.5% at 3 years, 55.9% at 5 years and 37.3% at 10 years).
In the present study, age was significantly different between the three groups. The median age at operation was 55-59 years in all groups. The reason for this age difference is unknown. We believe that patients who were introduced to dialysis at a young age had longer dialysis periods, and severe histological carcinoma occurred after >10 years of treatment. It is unclear why RCC patients having a long HD duration had a high probability of developing high-grade RCC. Previous reports suggest that RCC occurrence is dependent on factors such as calcium oxalate (CaOx), uraemia, a genetic mechanism (oncogene, antioncogene, mutagen), immunology or viral factors [12] [13] [14] [15] [16] [17] . CaOx is known to induce significant changes in cultured tubular cells; it may be mitogenic at lower concentrations but may cause cell necrosis or apoptosis at higher concentrations [18, 19] . CaOx can induce intracellular formation of reactive oxygen species and inhibit several cytosolic enzymes, which may account for its cytotoxic effects [18, 19] . In the context of ESRD, CaOx is thought to promote cyst and tumour formation via mechanical obstruction of renal tubules and through regulation of tubular cell cycles [11, [20] [21] [22] [23] . It is still unclear whether these factors also play important roles in the transformation of ordinary RCCs to cells having a sarcomatoid component. Further studies will be necessary to elucidate this possibility.
We found no evidence that early diagnosis and treatment of RCC in HD patients influenced their prognosis. We showed that long-term HD was one of the important prognostic factors because it may induce the transformation of ordinary RCCs to cells having a sarcomatoid component. We propose that careful follow-up will be necessary, especially for patients receiving long-term HD, and particularly for those having >10 years of HD. If RCCs are detected or suspected by medical examinations, early nephrectomy may be necessary for patients with >10 years of HD. It may also be necessary to perform prophylactic nephrectomy for patients having >10 years of HD. P-values < 0.05 considered significant; n.s., non-significant. 
